This GBM subtype shows a relative response to intensive treatment with temozolomide (TMZ) but a high resistance to radiotherapy, linked to the ability to NFκB (nuclear Factor kappa-light-chain-enhancer of activated B cells) activation and changes in their tumor microenvironment. Here, NFKB1 is linked to neoplasm.